Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Monday, 2 October 2017

Verona Pharma plc : Total voting rights

Verona Pharma plc    

Published: 08:00 CEST 02-10-2017 /GlobeNewswire /Source: Verona Pharma plc / : VRP /ISIN: GB00BYW2KH80

Verona Pharma plc : Total voting rights

October 2, 2017, LONDON - Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), in conformity with DTR 5.6 of the FCA's Disclosure and Transparency Rules, notifies the market that as at 30 September 2017, the issued ordinary share capital of the Company consisted of 105,017,401 ordinary shares with voting rights attached (one vote per ordinary share). There are no ordinary shares held in treasury. 

The above total voting rights figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.


For further information, please contact:


Verona Pharma plc

Tel: +44 (0)20 3283 4200

Jan-Anders Karlsson, Chief Executive Officer


Stifel Nicolaus Europe Limited (Nominated Adviser and UK Broker)

Stewart Wallace / Jonathan Senior / Ben Maddison

Tel: +44 (0) 20 7710 7600


This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of Nasdaq Corporate Solutions clients. Source: Verona Pharma plc, 3 More London Riverside, London SE1 2RE, United Kingdom
If you would like to unsubscribe and stop receiving these e-mails click here.